Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 642-648

  Schreiber, Taylor H ^a   Wolf, Dietlinde ^a   Bodero, Maria ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

FoxP3; iTreg; nTreg; Regulatory T cell; Tumor microenvironment

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84880887899     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20298     Document Type: Article

References (36)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Jeffrey Weber, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http:// dx.doi.org/10.1056/NEJMoa1104621.
3. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755.
4. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405-9; PMID:22318517; http://dx.doi.org/10.1038/ nature10803.
5. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol- 031210-101324.
6. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87; PMID:18510923; http://dx.doi. org/10.1016/j.cell.2008.05.009.
7. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003; 100:10902-6; PMID:12947044; http://dx.doi. org/10.1073/pnas.1834479100.
8. Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 2005; 201:681-6; PMID:15753203; http://dx.doi.org/10.1084/jem.20041959.
9. Hindley JP, Ferreira C, Jones E, Lauder SN, Ladell K, Wynn KK, et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen- induced tumors. Cancer Res 2011; 71:736-46; PMID:21156649; http://dx.doi.org/10.1158/0008-5472.CAN-10-1797.
10. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-36; PMID:16179369; http://dx.doi.org/10.1182/blood- 2005-07-2737.
11. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007; 178:2155-62; PMID:17277120.
12. Bilate AM, Lafaille JJ. Induced CD4(+)Foxp3(+) Regulatory T Cells in Immune Tolerance. Annu Rev Immunol 2011; PMID:22224762.
13. Adeegbe D, Matsutani T, Yang J, Altman NH, Malek TR. CD4(+) CD25(+) Foxp3(+) T regulatory cells with limited TCR diversity in control of autoimmunity. J Immunol 2010; 184:56-66; PMID:19949075; http:// dx.doi.org/10.4049/jimmunol.0902379.
14. Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993; 90:4319-23; PMID:8483950; http://dx.doi.org/10.1073/ pnas.90.9.4319.
15. + repertoire during antiviral therapy. Nat Med 1998; 4:215-21; PMID:9461196; http:// dx.doi.org/10.1038/nm0298-215.
16. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114:4099-107; PMID:19706884; http://dx.doi.org/10.1182/blood-2009-04-217604.
17. Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Cutting edge: antigen-specific TGFbetainduced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol 2008; 181:8209-13; PMID:19050237.
18. + regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 2008; 180:2830-8; PMID:18292504.
19. Zhang H, Podojil JR, Chang J, Luo X, Miller SD. TGFbeta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol 2010; 184:6629-36; PMID:20483764; http://dx.doi.org/10.4049/jimmunol.0904044.
20. + T regulatory cells. J Immunol 2007; 178:4022-6; PMID:17371955.
21. Hänig J, Lutz MB. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J Immunol 2008; 180:1405-13; PMID:18209035.
22. + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172:4676-80; PMID:15067041.
23. Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 2011; 35:109-22; PMID:21723159; http://dx.doi.org/10.1016/j. immuni.2011.03.029.
24. + regulatory T cells rescue scurfy mice. Eur J Immunol 2008; 38:1814-21; PMID:18546144; http://dx.doi. org/10.1002/eji.200838346.
25. Davidson TS, Shevach EM. Polyclonal Treg cells modulate T effector cell trafficking. Eur J Immunol 2011; 41:2862-70; PMID:21728170; http://dx.doi. org/10.1002/eji.201141503.
26. + regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007; 179:4685-93; PMID:17878367.
27. Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol 2008; 181:1798-805; PMID:18641317.
28. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012; 482:395-9; PMID:22318520; http://dx.doi. org/10.1038/nature10772.
29. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125-38; PMID:18725522; http://dx.doi.org/10.1084/jem.20080099.
30. + T regulatory cell-mediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j. immuni.2009.04.010.
31. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102:5126-31; PMID:15795373; http://dx.doi.org/10.1073/pnas.0501701102.
32. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329-41; PMID:15780990; http:// dx.doi.org/10.1016/j.immuni.2005.01.016.
33. + regulatory T cells. Nat Immunol 2003; 4:330-6; PMID:12612578; http://dx.doi.org/10.1038/ni904.
34. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferongamma- dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61; PMID:9636188; http://dx.doi. org/10.1073/pnas.95.13.7556.
35. Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 2008; 205:1037-48; PMID:18411341; http://dx.doi. org/10.1084/jem.20072528.
36. Matsutani T, Ohmori T, Ogata M, Soga H, Kasahara S, Yoshioka T, et al. Comparison of CDR3 length among thymocyte subpopulations: impacts of MHC and BV segment on the CDR3 shortening. Mol Immunol 2007; 44:2378-87; PMID:17156844; http://dx.doi. org/10.1016/j.molimm.2006.10.026.